Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO

Successor To Be Selected At Extraordinary General Meeting In February

After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.

Word delisting on dark blue finance background
Nichi-Iko is set to be absorbed by a private equity firm • Source: Shutterstock

Troubled Nichi-Iko Pharmaceutical Co., Ltd. has revealed that it will be delisted from the Tokyo Stock Exchange early next year, as company president and CEO Yuichi Tamura announced his resignation from the role.

The delisting is expected to occur sometime during March or April 2023. Nichi-Iko’s 70,384,700 common shares valued at ¥20bn ($147.7m)...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business